Skip to main content

Table 1 Patient background characteristics (n = 53)

From: Genetic diagnostic features after failure of initial treatment with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors among non-small-cell lung cancer patients harboring EGFR mutations

Variable

Rebiopsy

(+)

(−)

T790M mutation

Positive

(n = 29)

Negative

(n = 17)

Unknown

(n = 7)

Sex

 Male

11

3

3

 Female

18

14

4

 Age (years) median (range)

74 (42 - 86)

72 (38 - 89)

70 (59 - 82)

Histology

 Adenocarcinoma

27

17

7

 others

2

0

0

EGFR mutation at initial diagnosis

 Exon 19 deletion

21

6

1

 L858R

8

9

5

 L861Q

0

1

0

 Exon 20 insertion

0

1

0

 Compound mutation

0

0

1

Smoking status

 Never

18

13

3

 Past

8

1

2

 Current

3

3

2

ECOG performance status

 0

20

12

3

 1

8

5

2

 2

1

0

1

 3

0

0

1

Stage at initial diagnosis

 IA - IIIC

10

3

3

 IVA - IVB

19

14

4

Surgical treatment

 No

13

6

3

 Yes

16

11

4

Radical Radiotherapy

 No

27

16

6

 Yes

2

1

1

Chemotherapy during treatment

 No

8

6

6

 Yes

21

11

1

Reason for termination of TKIs

 Ongoing

1

5

3

 Adverse events

0

1

3

 Tumor growth

14

3

0

 New lesions

14

8

1

“CEA at progression” / “nadir CEA”; median (range)

3.1 (1.1–170)

2.5 (1.3–7.88)

2.0 (0.5–3.57)

nadir CEA (ng/mL); median (range)

3.0 (0.8–36.9)

2.2 (1.0–78.9)

45.6 (1.4–198)

Medical Drugs at TKI naïve line

 Gefitinib

11

2

0

 Erlotinib

16

10

6

 Afatinib

2

5

1

  1. Abbreviations: ECOG Eastern Cooperative Oncology Group; TKI tyrosine kinase inhibitor; CEA carcinoembryonic antigen; “CEA at progression” / “nadir CEA” “Serum level of CEA at progression” divided by “Serum nadir level of CEA”; nadir CEA Serum nadir level of CEA